NEW YORK, March 29, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on IPXL, MRK, NVS, and PFE which can be accessed for free by signing up to www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com evaluates Impax Laboratories Inc. (NASDAQ: IPXL), Merck
Shares in Hayward, California headquartered Impax Laboratories Inc. rose slightly by 0.78%, ending Wednesday's trading session at $19.45. The stock recorded a trading volume of 501,781 shares. The Company's shares have gained 11.78% over the last three months and 51.95% over the past year. The stock is trading 3.74% above its 200-day moving average. Moreover, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have a Relative Strength Index (RSI) of 43.24.
On March 07th, 2018, research firm SunTrust initiated a 'Buy' rating on the Company's stock, with a target price of $24 per share.
On March 27th, 2018 at Impax Laboratories' special meeting of stockholders, its stockholders approved the previously announced business combination of the Company with Amneal Pharmaceuticals LLC. At the meeting, 51.8 million shares, or approximately 99% of votes cast, voted in favor of the business combination. Get the full research report on IPXL for free by clicking below at: www.wallstequities.com/registration/?symbol=IPXL
Kenilworth, New Jersey headquartered Merck & Co. Inc.'s stock climbed 2.49%, closing the day at $55.09 with a total trading volume of 12.67 million shares. The Company's shares have advanced 0.68% in the past month. The stock is trading 2.65% below its 50-day moving average. Additionally, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 47.28.
On March 12th, 2018, research firm Leerink Partners upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On March 20th, 2018, Merck, known as MSD outside the US and Canada, announced the appointment of Jennifer Zachary as General Counsel, effective April 16th, 2018. Zachary will be responsible for the Company's global legal, security and aviation, and environmental, health and safety organizations, and be a member of the Executive Committee. She succeeds Michael J. Holston. Access the free research report on MRK now by signing up at: www.wallstequities.com/registration/?symbol=MRK
On Wednesday, shares in Basel, Switzerland headquartered Novartis AG recorded a trading volume of 1.58 million shares. The stock ended the day 2.27% higher at $81.25. The Company's shares have advanced 8.58% over the past year. The stock is trading below its 200-day moving average by 3.74%. Furthermore, shares of Novartis, which researches, develops, manufactures, and markets a range of healthcare products worldwide, have an RSI of 42.08. Are you already registered with Wall St. Equities? Do so now for free, and get the report on NVS at: www.wallstequities.com/registration/?symbol=NVS
New York headquartered Pfizer Inc.'s stock rose slightly by 0.83%, finishing yesterday's session at $35.30. A total volume of 24.97 million shares was traded, which was above their three months average volume of 24.39 million shares. The Company's shares have advanced 3.34% over the past year. The stock is trading above its 200-day moving average by 0.29%. Additionally, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have an RSI of 40.17.
On March 20th, 2018, Pfizer announced that it will webcast of a conference call with investment analysts on May 01st, 2018, at 10:00 a.m. EDT. The purpose of the call is to provide an update on the Company's results, as reflected in its first-quarter 2018 performance report, which will be issued that morning. The webcast and performance report may be accessed on the Company's investor website. Aspiring Member, please take a moment to register below for your free research report on PFE at:www.wallstequities.com/registration/?symbol=PFE
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-drug-makers-stocks----impax-labs-merck-novartis-and-pfizer-300621567.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Complex regional pain syndrome (CRPS) is rare chronic pain disorder usually involving an arm or ...
Polyarthritis refers to pain in four or more joints simultaneously due to various causes ranging ...
Gardner or Gardner''s syndrome, also known as familial adenomatous polyposis (FAP), is an autosomal ...View All